JAK2 and non-small cell lung carcinoma: Gaining insights on the mechanisms underlying the advantage of Hiltonol and Hiltonol cocktail [Hiltonol+anti-IL6+AG490 (JAK2 inhibitor)+Stattic (STAT3 inhibitor)] is essential for the development of anticancer drug cocktail with improved specificity and avoidance of off-target effects, since NSCLC is notorious for its heterogeneity.